

14<sup>th</sup> November 2013

To my Japanese colleagues,

I write to support the use of human papillomavirus vaccine to prevent HPV-related diseases, especially cervical cancer. To achieve the maximum benefit, the vaccine should be given to teenage girls before sexual debut. Furthermore, a high coverage is required to achieve an impactful reduction in disease burden, which can only be achieved through active promotion by health officials and professionals. Any claims on adverse effects should be investigated and clarified as soon as possible. I wish the Japanese government would resolve this issue as soon as possible.

Prof. Paul K.S. Chan

MBBS (HK), MSc (Virology) (Lond), MD (CUHK), FRCPath, FHKCPath, FHKAM (Pathology)  
Chairman & Professor (Clinical), Department of Microbiology, Faculty of Medicine  
The Chinese University of Hong Kong